Evidence map›Paper›PMID 37988251›Full record

ArticleJournal of medical virology2023

The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.

Amanda M Buck, Amelia N Deitchman, Saki Takahashi, Scott Lu, Sarah A Goldberg, Aaron Bodansky, Andrew Kung, Rebecca Hoh, Meghann C Williams, Marian Kerbleski and 14 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Amanda M BuckDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0001-7193-0617
Amelia N DeitchmanDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
Saki TakahashiDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Aaron BodanskyDivision of Pediatric Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Andrew KungDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Meghann C WilliamsDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Marian KerbleskiDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
David P MaisonDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Tyler-Marie DeveauDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Sadie E MunterDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
James LombardoDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Terri WrinMonogram Biosciences, South San Francisco, California, USA.
Christos J PetropoulosMonogram Biosciences, South San Francisco, California, USA.
Matthew S DurstenfeldDivision of Cardiology, University of California San Francisco, San Francisco, California, USA.
Priscilla Y HsueDivision of Cardiology, University of California San Francisco, San Francisco, California, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Bryan GreenhouseDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · USIdeaya Biosciences (United States) · US

Funding

Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Clinical Pharmacology Approaches towards Accelerating HIV Cure InitiativesK23AI162249 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEITCHMAN, AMELIA N · 2021 to 2025
$957k
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
NHLBI NIH HHS K12 HL143961NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS K23 AI162249NIAID NIH HHS K24 AI144048NIAID NIH HHS K24 AI174971NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS R01 AI141003NIH HHS
6 · The paper itself

Abstract

The associations between longitudinal dynamics and the breadth of SARS-CoV-2 neutralizing antibody (nAb) response with various Long COVID phenotypes before vaccination are not known. The capacity of antibodies to cross-neutralize a variety of viral variants may be associated with ongoing pathology and persistent symptoms. We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and post-SARS-CoV-2 Omicron variants in participants infected early in the COVID-19 pandemic, before widespread rollout of SARS-CoV-2 vaccines. Cross-sectional regression models adjusted for clinical covariates and longitudinal mixed-effects models were used to determine the impact of the breadth and rate of decay of neutralizing responses on the development of Long COVID symptoms, as well as Long COVID phenotypes. We identified several novel relationships between SARS-CoV-2 antibody neutralization and the presence of Long COVID symptoms. Specifically, we show that, although nAb responses to the original, infecting strain of SARS-CoV-2 were not associated with Long COVID in cross-sectional analyses, cross-neutralization ID

Indexed as

COVID-19Post-Acute COVID-19 SyndromeAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCross-Sectional StudiesHumansPandemicsSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCOVID-19, SARS-CoV-2Long COVIDneutralizing antibodiespost-acute sequelae of SARS-CoV-2 infection (PASC)

Identifiers

PMID37988251
PMCPMC10754238
OpenAlexW4388894493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.